Current Projects Using SEER-MHOS Data

The following current projects are using SEER-MHOS data under data use agreements, shared with permission from the listed Principal Investigators.

Updated 23 March 2017

Project ID: 2013-021

Principal Investigator(s)
Alberts, David S.
Project Title
Assessment of cancer clinical, economic and humanistic outcomes among underserved.
Institution
University of Arizona Cancer Center.
Cancer Site(s)
Esophagus, Stomach, Colorectal, Liver & bile duct, Breast, Cervix, Prostate, Non-Cancer.
Aims
Assess the health-related quality of life (HRQOL) of underserved racial/ethnic populations that have been diagnosed with breast, cervical, colorectal, and prostate cancer.

Project ID: 2011-006

Principal Investigator(s)
Chen, Ronald.
Project Title
Appropriateness of Aggressive Cancer Treatment Based on Life Expectancy.
Institution
University of North Carolina at Chapel Hill.
Cancer Site(s)
Colorectal, Lung & bronchus, Breast, Prostate, Non-Cancer.
Aims

"The goal of this study is to examine the patterns of aggressive cancer care in different patient strata by life expectancy. For many cancers, such as prostate cancer, aggressive treatment may involve surgery and/or multi-modality therapy. However, for older patients and those with comorbidities, often less aggressive treatment is pursued.

Using patient age and existing comorbidities prior to cancer diagnosis (which are available in the SEER-MHOS dataset (the investigators will categorize patients into different life expectancy groups. Then in each group, patterns of care in terms of treatments received will be examined. While patterns of care studies are common in the cancer literature, how patient life expectancy affects aggressiveness of cancer treatment is not a well-studied subject. The latter is the focus of this proposed study."

Project ID: 2015-042

Principal Investigator(s)
Clark, Clancy.
Project Title
Health-related Quality for Life for Cancer Survivors Treated with Surgery (Revised).
Institution
Wake Forest Baptist Health.
Cancer Site(s)
Colorectal, Lung & bronchus, Breast, Prostate.
Aims
  1. To investigate the feasibility of a study using the Surveillance, Epidemiology, and End Results- Medicare Health Outcomes Survey (SEER-MHOS) linked database to measure health-related quality of life in cancer survivors treated with an operation.
  2. To characterize the physical and mental health of patients diagnosed with cancer using a large population-based database.
  3. To compare self-reported physical and mental health between cancer survivors treated with and without surgical resection after controlling for age, race, socioeconomic status, co-morbidities, cancer histology, and cancer stage.
  4. To compare self-reported physical and mental health between cancer and noncancer patients after controlling for age, race, co-morbidities, and socioeconomic status.
  5. To examine disparities in cancer outcomes and its underlying attributes.

Project ID: 2016-049

Principal Investigator(s)
Cote, Michele L.
Project Title
Impact of cancer diagnosis and treatment on HRQOL in Black and minority elderly women with GYN cancer.
Institution
Wayne State University School of Medicine.
Cancer Site(s)
Breast, Cervix, Uterus, Ovary.
Aims
  1. To describe racial differences in self-reported HRQOL in women after gynecologic cancer diagnosis compared to propensity-matched non-cancer controls.
  2. To describe racial differences in self-reported HRQOL in gynecologic cancer patients compared to a cohort of breast cancer patients.
  3. To examine factors associated with poor HRQOL in women diagnosed with gynecologic cancer.

Project ID: 2016-055

Principal Investigator(s)
Duarte, Christine.
Project Title
Prediction of Six Month Mortality in Cancer Patients.
Institution
Maine Medical Center Research Institute.
Cancer Site(s)
Colorectal, Lung & bronchus, Breast, Prostate.
Aims
  1. Measure the calibration and discrimination of the original PROMPT in the sample of SEER-linked cancer patients for the top four cancers (breast, prostate, lung, and colorectal).
  2. Using the SEER variables in addition to the MHOS data, develop a cancer-specific model to predict six month mortality in the four most prevalent cancers, first for combined cancer and then for each of the four cancers separately.

Project ID: 2015-045

Principal Investigator(s)
Friese, Chris
Project Title
Heart Failure in Women Who Survive Breast Cancer: Health-Related Quality of Life.
Institution
University of Michigan School of Nursing.
Cancer Site(s)
Breast.
Aims
Aim 1. Compare 8 domains of HRQL among four groups of women age 65 and older: Group 1 (BrCa+HF): women with a history of breast cancer and HF; Group 2 (BrCa): women with a history of breast cancer but no history of HF; Group 3 (HF): women with HF but no history of cancer; Group 4 (NoCaHF): healthy women with no history of cancer or heart failure. To control for demographic and clinical variables, women in groups 2, 3, and 4 will be identified based on propensity score matching with women in group 1.25 Hypothesis 1. At two-year follow-up, women in the BrCa+HF group have the poorest HRQL in the following domains: physical functioning, general health, vitality, and mental health.

Aim 2. Among the four groups, compare how each of the 8 domains of HRQL changes over time, from baseline to two years later. Hypothesis 2. Over the two-year period, women in the BrCa+HF group have the greatest decline in HRQL in the domains of physical functioning, general health, vitality, and mental health.

Aim 3. For all women in the sample, determine the relationship between baseline HRQL and diagnosis status (breast cancer and HF diagnoses) and HRQL at two-year follow-up in each of the 8 domains. Hypothesis 3. Baseline HRQL and diagnoses of breast cancer and HF predict HRQL at two years.

Project ID: 2015-039

Principal Investigator(s)
Huang, Min.
Project Title
Impact of cancer on health-related QoL, ADLs, and falls in older Medicare Beneficiaries.
Institution
University of Michigan-Flint.
Cancer Site(s)
Colorectal, Lung & bronchus, Breast, Uterus, Prostate, Bladder, Kidney & renal pelvis, Lymphomas.
Aims
  1. To examine the changes in HRQOL, prevalence in limitations in ADLs, problems with balance or walking, fall risk management, and falls after the cancer diagnosis in older cancer survivors.
  2. To evaluate the relationship between cancer-related clinical variables, HRQOL, ADLs, balance or walking, and falls in cancer survivors after their cancer diagnosis.
  3. To identify among variables at baseline, including cancer-related clinical variables, HRQOL, limitations in ADLs, problems with balance or walking, fall risk management, and the previous history of falls, the unique factors predictive of falls in older cancer survivors.
  4. Develop evidence-based clinical algorithms to optimize the outcomes including problems with balance or walking as well as falls in older cancer survivors.

Project ID: 2014-033

Principal Investigator(s)
Kenzik, Kelly.
Project Title
Understanding multi-morbidity in cancer to enhance palliative and supportive care.
Institution
University of Alabama at Birmingham.
Aims
  1. Identify comorbidity clusters of multi-morbidities pre- and post- cancer diagnosis across cancer types.
  2. Determine the symptom burden associated with different multi-morbidity clusters among cancer patients.
  3. Determine the functional limitations associated with different multi-morbidity clusters among cancer patients.

Project ID: 2016-057

Principal Investigator(s)
Mehra, Saral.
Project Title
Impact of Treatment for Head and Neck Cancer on Health Related Quality of Life.
Institution
Yale University.
Cancer Site(s)
Oral cavity & pharynx, Nose, Nasal cavity, Larynx, Endrocine sytem/Thyroid.
Aims
  1. Patients completing a MHOS survey after initiation of treatment for HNC will have inferior HRQOL and ability to perform ADLs compared to patients completing a MHOS survey before initiation of treatment for HNC (see part 1 below).
  2. Differences in HRQOL and ability to perform ADLs in patients completing a MHOS survey before versus after initiation of treatment will be affected by tumor-, treatment and patient-specific variables, including specific tumor subsite (oral cavity, nasopharynx, oropharynx & tonsil, larynx & hypopharynx, and salivary gland) and the interval of time between treatment initiation and survey completion (see part 1 below).
  3. Patients completing a MHOS survey after initiation of treatment for thyroid cancer will have inferior HRQOL and ability to perform ADLs compared to patients completing a MHOS survey before initiation of treatment for thyroid cancer (see part 2 below).
  4. Differences in HRQOL and ability to perform ADLs before versus after initiation of treatment in patients with laryngeal or hypopharyngeal cancer will be affected by initial treatment modality (see part 3 below).
  5. Differences in HRQOL and ability to perform ADLs before versus after initiation of treatment in patients with oropharyngeal or tonsil cancer will be affected by initial treatment modality (see part 4 below).

Project ID: 2015-043

Principal Investigator(s)
Min, Hua
Project Title
Applying the Ontology-guided Machine Learning to analyze the SEER-MHOS Linked Database.
Institution
George Mason University.
Cancer Site(s)
Oral cavity & pharynx, Stomach, Colorectal, Pancreas, Lung & bronchus, Nose, Nasal cavity, Larynx, Skin (excl. basal & squamous), Breast, Uterus, Prostate, Bladder.
Aims
Aim 1. Develop an ontology-guided ML method that allows for analyzing heterogeneous healthcare datasets.

Aim 2. Test the ontology-guided ML method to analyze the SEER-MHOS dataset.

Aim 3. Investigate the associations between the quality of life (QoL), survival, and other characteristics in patients with cancer.

Project ID: 2014-030

Principal Investigator(s)
Mohile, Supriya G.
Project Title
Predictors of Poor QOL and Association with Outcomes in Vulnerable Older Adults with Cancer.
Institution
University of Rochester Medical Center.
Cancer Site(s)
Oral cavity & pharynx, Stomach, Colorectal, Pancreas, Lung & bronchus, Nose, Nasal cavity, Larynx, Breast, Cervix, Uterus, Ovary, Other female genital system, Prostate, Bladder, Kidney & renal pelvis, Non-Cancer.
Aims
  1. To explore racial/ethnic disparities in clinical outcomes (including quality of life) of vulnerable elders with cancer with those who are not vulnerable.
  2. To identify clinical and contextual predictors of poor outcomes for African American older adults with cancer.

Project ID: 2016-052

Principal Investigator(s)
Payakachat, Nalin.
Project Title
Health-related Quality of Life among Older Americans with Cancers: A Population-based Study.
Institution
University of Arkansas for Medical Sciences.
Cancer Site(s)
Oral cavity & pharynx, Lung & bronchus, Cervix, Uterus, Ovary, Other female genital system, Bladder, Kidney & renal pelvis, Urinary system, Multiple myeloma.
Aims

Specific Aim 1: Compare HRQoL and health utility changes among selected cancer patients across disease stages and type of cancer from before to after cancer diagnosis with matched non-cancer controls.

Specific Aim 2: Assess HRQoL and health utility changes among selected cancer patients across initial course of treatment from before to after cancer diagnosis with matched non-cancer controls.

Specific Aim 3: Determine HRQoL and health utility changes among selected cancer patients across race/ethnicity from before to after cancer diagnosis with matched non-cancer controls.

Project ID: 2015-037

Principal Investigator(s)
Reeve, Bryce B.
Project Title
Changes in HRQOL among survivors of lung, prostate, bladder, and gynecological cancers.
Institution
University of North Carolina.
Cancer Site(s)
Lung & bronchus, Cervix, Uterus, Ovary, Other female genital system, Prostate, Bladder.
Aims
  1. Examine changes in HRQoL from before to after cancer among Medicare Beneficiaries stratified by treatment type and burden of comorbid health conditions.
  2. Compare the impact of cancer, treatment type, and comorbid conditions on Medicare beneficiaries' lives relative to matched controls without cancer.
  3. Conduct in-depth analyses by cancer treatment type to examine clinical and sociodemographic factors that may be associated with HRQoL declines for Medicare beneficiaries with cancer.

Project ID: 2013-025

Principal Investigator(s)
Schade, George; Wright, Jonathan L.
Project Title
Health Related Quality of Life Among Medicare Beneficiaries with Urological Malignancies.
Institution
University of Washington, Dept. of Urology.
Cancer Site(s)
Prostate, Bladder, Kidney & renal pelvis, Non-Cancer.
Aims
  1. To determine the effect of different treatment approaches for common urologic malignancies (prostate, kidney and bladder) on patient reported HRQoL.
  2. To evaluate the change in patient reported HRQoL compared to healthy controls following diagnosis and treatment of bladder, kidney and prostate cancer.

Project ID: 2015-044

Principal Investigator(s)
Schade, George R.; Wright, Jonathan L.
Project Title
Health Related Quality of Life Among Medicare Beneficiaries with Urological Malignancies (update).
Institution
University of Washington.
Cancer Site(s)
Colorectal, Prostate, Bladder, Kidney & renal pelvis.
Aims
Aim 1. To determine the effect of different treatment approaches for common urologic malignancies (prostate, kidney and non-muscle invasive bladder) on patient reported HRQoL.

Aim 2. To evaluate the change in patient reported HRQoL compared to healthy controls following diagnosis and treatment of non-muscle invasive bladder, kidney, and prostate cancer.

Aim 3. To assess the change in patient reported HRQoL of muscle invasive bladder cancer patients undergoing radical cystectomy with urinary diversion (ileal conduit) compared to colo-rectal cancer patients undergoing extirpative surgery with colostomy or ileostomy.

Project ID: 2016-053

Principal Investigator(s)
Tibbitts, Deanne.
Project Title
Secular Trends in Health-Related Quality of Life Among Older Women with Breast Cancer, 1998-2013.
Institution
National University of Natural Medicine.
Cancer Site(s)
Breast, Non-Cancer.
Aims

Specific Aim 1: To analyze secular trends in post-diagnosis HRQOL among OWBC from 1998-2013.

Hypothesis: Post-diagnosis HRQOL has improved among OWBC from 1998-2013.

Specific Aim 2: To analyze secular trends in changes in HRQOL during the pre- to post-diagnosis period from 1998-2013 among OWBC and to compare them to secular trends in changes in HRQOL from baseline to follow-up survey among older women without cancer.

Hypothesis: During the pre- to post-diagnosis period, changes in HRQOL among OWBC have decreased more than changes in HRQOL in the non-cancer population from 1998-2013.

Specific Aim 3: To analyze secular trends in differences in HRQOL between OWBC and matched, non-cancer controls from 1998-2013.

Hypothesis: Differences in HRQOL between OWBC and matched, non-cancer controls have decreased from 1998-2013.

Project ID: 2013-026

Principal Investigator(s)
Ware, John E.; Frendl, Daniel M.
Project Title
Using Patient-Reported Data to Improve Treatment Decisions for Older Men With Prostate Cancer.
Institution
University of Mass Medical School.
Cancer Site(s)
Prostate.
Aims
  1. To describe the patient factors associated with prostate cancer treatment allocation (aggressive vs. conservative therapies) and to identify factors associated with patients dying of prostate cancer versus other causes of death.
  2. To identify predictors (patient factors, quality of life indicators, and information routinely collected in clinical practice) of 5- and 10-year other cause mortality among men with prostate cancer.
  3. To develop a risk calculator from risk prediction models using a subset of variables routinely available in clinical practice to predict 10-year risk of other cause mortality.
  4. Using the prediction scores derived from Specific Aim 2, to estimate the cost of evidenced-based, appropriately aggressive, care delivery vs. actual care received as reported in SEER, among men with prostate cancer, stratified across levels of other cause mortality risk.

Project ID: 2015-036

Principal Investigator(s)
Wildes, Tanya.
Project Title
The Epidemiology of Multiple Myeloma.
Institution
Washington University School of Medicine.
Cancer Site(s)
Multiple myeloma.
Aims
Retrospective data analyses to determine the associations of race, socioeconomic status (SES), comorbidities, etc. with multiple myeloma (MM) survival, MM treatment, healthcare utilization etc.

Project ID: 2016-054

Principal Investigator(s)
Wisnivesky, Juan.
Project Title
Optimizing Treatment of Lung Cancer Patients with Comorbidities.
Institution
Mount Sinai Health System.
Cancer Site(s)
Lung & bronchus.
Aims
  1. The LCPM can accurately represent the natural history, treatment, and outcomes of lung cancer patients with chronic lung, heart, and renal disease as well as by overall burden of comorbidities.
  2. Stage I NSCLC patients with severe comorbidities will benefit from less aggressive forms of therapy.
  3. Stage II and IIIA NSCLC patients with moderate to severe chronic lung, heart, or renal disease or with high burden of comorbidities will not benefit from adjuvant chemotherapy.
  4. Resection will lead to better outcomes than chemoradiotherapy in limited stage SCLC patients with severe renal disease or high burden of comorbidities.

Project ID: 2013-017

Principal Investigator(s)
Yu, James B.
Project Title
Measuring and comparing the health utility of patients who have undergone modern cancer therapy.
Institution
Yale School of Medicine.
Cancer Site(s)
Colorectal, Lung & bronchus, Breast, Prostate, Non-Cancer.
Aims
  1. Calculate the health utility of patients before and after cancer treatment, by converting the SF-36 data to a single health utility.
  2. Compare the impact of different cancer treatments on changes to health utility.
  3. Incorporate the impact of cancer treatment and its changes to a patient's measured health utility on modifying the measurement of comparative effectiveness that has been measured without incorporating health utility.

Project ID: 2016-050

Principal Investigator(s)
Yu, James B.
Project Title
Measuring and comparing the health utility of patients who have undergone modern cancer therapy.
Institution
Yale School of Medicine.
Cancer Site(s)
Lung & bronchus, Breast, Prostate, Bladder, Non-Cancer.
Aims

Specific Aim 1) Calculate the health utility of patients before and after cancer treatment, by converting the SF-36 data to a single health utility.

Specific Aim 2) Compare the impact of different cancer treatments on changes to health utility.

Specific Aim 3) To incorporate the impact of cancer treatment and its changes to a patient's measured health utility on modifying the measurement of comparative effectiveness that has been measured without incorporating health utility.